SAI LIFE SCIENCES (SAILIFE) Share Price Falls 2.72% Today
- September 10, 2026
- Posted by: Harsh Piplani
- Category: News
SAI LIFE SCIENCES Share Price fell to Rs 1,629.65 on 10 September 2026, down 2.72% or Rs 45.50 for the day. At that level, the company’s market capitalisation stood at Rs 34,967.52 crore. The stock opened at Rs 1,679.85 and later touched an intraday low of Rs 1,625.50, keeping the counter in focus during the session.
The available data confirms the decline but does not identify a company-specific catalyst behind it. Even so, the move is notable because it comes alongside elevated valuation ratios, above-industry profitability metrics and a market-cap profile that is larger than the average company in its benchmark set.
For readers tracking SAI LIFE SCIENCES Share Price Today, the supplied snapshot offers a clear picture: turnover was Rs 1.05 crore, the stock is classified as Large Cap, P/E stood at 98.36, P/B at 13.94, ROE at 15.16% and ROCE at 20.97%. Those figures help place today’s price action in a broader fundamental and sector context.
SAI LIFE SCIENCES (SAILIFE) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,629.65 |
| Previous Close | Rs 1,675.15 |
| Today's Move | -Rs 45.50 (-2.72%) |
| Open | Rs 1,679.85 |
| High | Rs 1,679.85 |
| Low | Rs 1,625.5 |
| Turnover | Rs 1.05 crore |
| Market Capitalisation | Rs 34,967.52 crore |
| Market Cap Category | Large Cap |
SAI LIFE SCIENCES Share Price Today reflects a clear intraday decline. The stock opened at Rs 1,679.85, which was also the session high, then moved lower to Rs 1,625.50 before trading at Rs 1,629.65. Compared with the previous close of Rs 1,675.15, that amounts to a loss of Rs 45.50.
The open and high being the same is a useful intraday detail because it shows the stock did not move above its initial level during the session. The gap between the day’s high and low was Rs 54.35, indicating a meaningful trading range. Turnover of Rs 1.05 crore points to active trading, though the data provided does not by itself explain why the stock came under pressure.
For market participants, this kind of session usually matters less in isolation and more when viewed alongside valuation, profitability and relative positioning within the Pharmaceuticals & Drugs space. That is where the rest of the data becomes relevant.
SAI LIFE SCIENCES (SAILIFE) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 34,967.52 crore |
| P/E Ratio | 98.36x |
| P/B Ratio | 13.94x |
| ROE | 15.16% |
| ROCE | 20.97% |
| EPS | Rs 17.03 |
| Book Value Per Share | Rs 120.19 |
| Dividend Yield | 0% |
The fundamental picture shows a sizeable listed company, but one trading at rich multiples. A P/E ratio of 98.36 and P/B ratio of 13.94 place the stock well above what many investors would consider ordinary sector valuations. That alone can keep the counter under scrutiny when the market price declines.
At the same time, profitability metrics are not weak. ROE stands at 15.16% and ROCE at 20.97%, suggesting the business has been generating returns above many industry reference points. EPS is Rs 17.03, while book value per share is Rs 120.19. Dividend yield is listed as 0%, so the present dataset does not show a dividend yield contribution.
Put together, the numbers indicate a stock where market pricing remains demanding relative to its accounting base and earnings, while operating return ratios appear comparatively solid. That combination often leads investors to watch whether the premium valuation continues to hold during weaker sessions.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 98.36x |
| Benchmark Median P/E | 32.79x |
| Benchmark Average P/E | 49.1x |
| Benchmark P/E Range | 3.4x to 706.55x |
| Company P/B Ratio | 13.94x |
| Benchmark Median P/B | 3x |
| Benchmark Average P/B | 4.44x |
| Company ROE | 15.16% |
| Benchmark Median ROE | 11.83% |
| Benchmark Average ROE | 11.27% |
| Company ROCE | 20.97% |
| Benchmark Median ROCE | 13.75% |
| Benchmark Average ROCE | 13.75% |
| Company Market Capitalisation | Rs 34,967.52 crore |
| Benchmark Median Market Cap | Rs 759.52 crore |
| Benchmark Average Market Cap | Rs 14,312.16 crore |
SAI LIFE SCIENCES operates in Healthcare, within the Pharmaceuticals & Drugs industry. The benchmark supplied covers 200 companies from the same industry, which gives useful context for comparing the company’s valuation, profitability and scale with broader listed peers.
On valuation, the stock sits well above benchmark norms. Its P/E of 98.36 is higher than the industry median of 32.79 and average of 49.1. Its P/B of 13.94 is also far above the median of 3 and average of 4.44. Those comparisons suggest the market is assigning a premium to the company relative to a large part of the industry universe.
Profitability looks different. ROE of 15.16% is above the industry median of 11.83% and average of 11.27%, while ROCE of 20.97% is above both the median and average of 13.75%. This means valuation is rich, but return ratios are also better than the benchmark averages.
In terms of size, the company’s market cap of Rs 34,967.52 crore is well above the benchmark median of Rs 759.52 crore and the benchmark average of Rs 14,312.16 crore. So, within the industry set, the business is not small, even though its scale remains below the largest pharma names.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,51,338.9 | 37.06 | 5.18 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,54,068.03 | 86.06 | 14.25 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,88,767.06 | 86.01 | 20.9 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,14,712.94 | 24.95 | 4.18 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,11,803.57 | 32.79 | 3.14 | 11.83 | 16 |
Against prominent pharma peers, SAI LIFE SCIENCES Share Price screens as expensive on both earnings and book value multiples. Its P/E of 98.36 is higher than Sun Pharmaceutical Industries at 37.06, Zydus Lifesciences at 24.95 and Cipla at 32.79, and it is also above Divi’s Laboratories at 86.06 and Torrent Pharmaceuticals at 86.01.
Its P/B of 13.94 is above Sun Pharma’s 5.18, Zydus’s 4.18 and Cipla’s 3.14, while sitting slightly below Divi’s 14.25 and below Torrent’s 20.90. On profitability, the comparison is more mixed. ROE of 15.16% is above Sun Pharma and Cipla, close to Divi’s, but below Zydus and Torrent. ROCE of 20.97% is above Sun Pharma and Cipla, close to Divi’s and Zydus, and above Torrent’s 19.27.
Scale is where the gap is clearer. SAI LIFE SCIENCES, at Rs 34,967.52 crore, is materially smaller than all five listed peers in the comparison table. That leaves investors looking at a stock with premium valuation, competitive return ratios and a smaller market-cap base than established sector leaders.
Why Investors Are Watching SAI LIFE SCIENCES
- The stock fell 2.72% today to Rs 1,629.65 from the previous close of Rs 1,675.15.
- It opened at Rs 1,679.85, which was also the session high, and later touched Rs 1,625.50.
- Valuation remains elevated with P/E at 98.36 and P/B at 13.94.
- Profitability is above benchmark averages, with ROE at 15.16% and ROCE at 20.97%.
- The company is much larger than the benchmark median firm, but still smaller than major named pharma peers.
About SAI LIFE SCIENCES
SAI LIFE SCIENCES is mapped to the Healthcare sector and the Pharmaceuticals & Drugs industry. It is classified as a Large Cap company, with a market value of Rs 34,967.52 crore in the supplied dataset. Within the same industry set, it is compared with companies such as Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla. That placement helps readers interpret whether the current pricing sits closer to sector norms or at a premium to them.
Track SAI LIFE SCIENCES Share Price on Univest
UseSAI LIFE SCIENCES (SAILIFE) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
On Univest, investors can follow SAI LIFE SCIENCES Share Price through live price tracking, valuation ratios, peer comparison and sector benchmark data in one place. That makes it easier to read today’s decline alongside longer-form company and industry context rather than treating a single session move as a complete explanation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is SAI LIFE SCIENCES Share Price falling today?
Ans. SAI LIFE SCIENCES Share Price is down 2.72% today at Rs 1,629.65 versus the previous close of Rs 1,675.15. The supplied data confirms the decline, but it does not establish any company-specific reason for the move.
What is SAI LIFE SCIENCES Share Price Today?
Ans. SAI LIFE SCIENCES Share Price Today is Rs 1,629.65. The stock has declined by Rs 45.50 in the session from the previous close of Rs 1,675.15. The stock moved 2.72% lower during the session.
What does today’s price action show for SAI LIFE SCIENCES?
Ans. The stock opened at Rs 1,679.85, which was also the day’s high, and later slipped to Rs 1,625.50 before trading at Rs 1,629.65. That pattern shows the stock failed to hold its opening level during the session.
What is the market capitalisation of SAI LIFE SCIENCES?
Ans. SAI LIFE SCIENCES has a market capitalisation of Rs 34,967.52 crore. That places it in the Large Cap category and above the Pharmaceuticals & Drugs benchmark average of Rs 14,312.16 crore.
Is SAI LIFE SCIENCES expensive compared with its industry?
Ans. On the supplied numbers, the stock trades at a P/E of 98.36 against the industry median of 32.79 and average of 49.1. Its P/B of 13.94 is also above the benchmark median of 3 and average of 4.44.
How profitable is SAI LIFE SCIENCES compared with the benchmark?
Ans. ROE stands at 15.16%, above the industry median of 11.83% and average of 11.27%. ROCE is 20.97%, above the benchmark median and average of 13.75%. Comparable listed companies include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals.
How does SAI LIFE SCIENCES compare with Sun Pharma and Divi’s?
Ans. The company trades at a higher P/E of 98.36 than Sun Pharma at 37.06 and Divi’s at 86.06. Its ROE of 15.16% is above Sun Pharma’s 14.85% but below Divi’s 16.19%.
Is SAI LIFE SCIENCES larger or smaller than major pharma peers?
Ans. At Rs 34,967.52 crore, SAI LIFE SCIENCES is smaller than the named peers in the supplied comparison set, including Sun Pharma, Divi’s, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla. Comparable listed companies include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals.
What should investors monitor next in SAI LIFE SCIENCES stock updates?
Ans. Investors may watch whether the stock stabilises after today’s 2.72% decline while keeping an eye on its premium valuation, return ratios and relative positioning within the Pharmaceuticals & Drugs industry.
